TMEM180 Activators
TMEM180 Activators encompass a diverse array of chemical compounds that indirectly contribute to the enhanced functional activity of TMEM180 by modulating various cellular signaling pathways. Forskolin and IBMX, through the elevation of intracellular cAMP levels, activate PKA signaling, which could lead to the phosphorylation of proteins related to TMEM180, thus enhancing its activity. Caffeine and 8-Br-cAMP, also acting through cAMP and PKA pathways, further support this mechanism of TMEM180 activation. PMA activates PKC, which is known for its role in protein trafficking and localization, potentially influencing the functional engagement of TMEM180 at specific cellular locales. On the lipid signaling front, S1P activates downstream kinases like ERK, PI3K, and PKC, which may affect TMEM180 by altering its cellular context or through direct protein interactions.
Similarly, compounds affecting intracellular calcium levels, such as Ionomycin and Thapsigargin, lead to the activation of calcium-dependent signaling mechanisms that could modify the activity or localization of TMEM180. EGCG's activity by reducing competition among signaling pathways, possibly leading to enhanced TMEM180 activity. On the kinase inhibition front, LY294002, U0126, and SB203580 act as inhibitors of PI3K, MEK, and p38 MAPK, respectively. These inhibitors can indirectly promote TMEM180 activity by altering the balance of cellular signaling pathways, allowing TMEM180 functions to be more prominently exerted. For example, the reduction in ERK signaling due to U0126 may shift the signaling equilibrium to favor pathways that TMEM180 is involved in, thereby enhancing its activity. Collectively, these TMEM180 Activators work through distinct biochemical mechanisms, yet they all converge on the common outcome of elevating the functional activity of TMEM180 without directly increasing its expression or requiring its direct activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP) within cells. Elevated cAMP can enhance the activity of TMEM180 by promoting cAMP-dependent protein kinase A (PKA) signaling, which may phosphorylate proteins that interact with or regulate TMEM180. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP. By preventing cAMP degradation, IBMX can indirectly lead to the activation of PKA and subsequent phosphorylation cascades that could enhance the activity of TMEM180. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a protein kinase C (PKC) activator. PKC signaling can modulate the trafficking and localization of TMEM180, leading to its enhanced functional activity at specific cellular sites. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, possibly affecting the activity of calcium-dependent kinases and phosphatases that could modify the function or localization of TMEM180. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that inhibits several protein kinases. Inhibition of these kinases could reduce competitive signaling, potentially allowing TMEM180 pathways to become more active or accessible within the cell. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, which may lead to the activation of downstream kinases such as ERK, PI3K, and PKC. These kinases could influence the activity of TMEM180 through direct interactions or by altering its cellular context. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium. Elevated calcium levels can activate calcium-dependent signaling pathways, potentially enhancing the function of TMEM180. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can modulate downstream signaling pathways such as AKT, which may indirectly lead to the enhanced activity of TMEM180 by altering cellular localization or protein-protein interactions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which can lead to reduced ERK signaling. The inhibition of this pathway may allow TMEM180 to become more functionally active by shifting the balance of signaling pathways within the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it could enhance TMEM180 activity indirectly by modulating stress response pathways that intersect with TMEM180's functional role. | ||||||